dostarlimab

Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes

OncLive - 23 Aug 2024
Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes ...

Dostarlimab Benefits Appear More Pronounced in dMMR Endometrial Cancer

Cancer Network - 16 Aug 2024
Dostarlimab Benefits Appear More Pronounced in dMMR Endometrial Cancer ...

Dostarlimab's Promise in dMMR Locally Advanced Rectal Cancer

Targeted Oncology - 31 Oct 2024
Dostarlimab's Promise in dMMR Locally Advanced Rectal Cancer ...

Optimizing PD-1 Combination Therapy for Advanced and Recurrent Endometrial Cancer

Cancer Therapy Advisor - 22 Nov 2024
Optimizing PD-1 Combination Therapy for Advanced and Recurrent Endometrial Cancer ...

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer

Frontiers - 19 Jun 2024
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer ...

FDA Expands Approval of Dostarlimab for Advanced, Recurrent Endometrial Cancer

www.oncnursingnews.com/ - 01 Aug 2024
FDA Expands Approval of Dostarlimab for Advanced, Recurrent Endometrial Cancer ...

US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit

Business Wire - 01 Aug 2024
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit ...

A 100% response rate suggests dostarlimab is ‘definitive’ therapy for rectal cancer

Healio - 05 Jun 2024
A 100% response rate suggests dostarlimab is ‘definitive’ therapy for rectal cancer ...

Pipeline

GSK - 30 Oct 2024
Pipeline ...

Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer

OncLive - 07 Nov 2024
Dr Powell on the Implications of the FDA Approval of Dostarlimab for Endometrial Cancer ...

Dostarlimab: Game Changer in Rectal Cancer Treatment?

Targeted Oncology - 17 Jun 2024
Dostarlimab: Game Changer in Rectal Cancer Treatment? ...

Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers

Cancer Network - 24 Apr 2024
Dostarlimab Earns FDA Priority Review in All Advanced Endometrial Cancers ...

Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC

OncLive - 14 Sep 2024
Frontline Belrestotug/Dostarlimab Boosts Responses Vs Dostarlimab Alone in PD-L1–High NSCLC ...

Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer

OncLive - 03 Jul 2024
Dostarlimab/Chemo Shows OS Benefit Regardless of MMR Status in Endometrial Cancer ...

Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC

OncLive - 08 Nov 2024
Frontline Dostarlimab/Chemo Maintains Numerical OS Benefit in Advanced NSCLC ...

Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer

OncLive - 25 Jun 2024
Dostarlimab/Chemo/Niraparib Generates PFS Benefit in Primary/Recurrent Endometrial Cancer ...

Dostarlimab Wins Full Approval in Canada for dMMR/MSI-H Endometrial Cancer

OncLive - 25 Jul 2024
Dostarlimab Wins Full Approval in Canada for dMMR/MSI-H Endometrial Cancer ...

FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer

OncLive - 26 Aug 2024
FDA Approval Insights: Dostarlimab Plus Chemotherapy in Advanced/Recurrent Endometrial Cancer ...

Dr Powell on the FDA Approval of Dostarlimab Plus Chemo in Advanced/Recurrent Endometrial Cancer

OncLive - 04 Sep 2024
Dr Powell on the FDA Approval of Dostarlimab Plus Chemo in Advanced/Recurrent Endometrial Cancer ...